Paper Details

  1. Home
  2. Paper Details

[Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia].

Author: ChenHonghui, FangMaosheng, OuJianjun, ShaoPing, WuRenrong, XuYi, ZhaoJingping

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 245 patients with first-episode schizophrenia found that ziprasidone had less of an effect on glucose and lipid metabolism than olanzapine in short-term treatment. Patients treated with olanzapine had higher weight gain and significant increases in FBS, fasting insulin, HDL, TC, TG, LDL, and IRI levels, which is associated with an increased risk of complications.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To investigate the effect of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia. METHODS: A total of 260 schizophrenics were assigned randomly to receive ziprasidone or olanzapine for 6 weeks. The weight was measured at baseline, week 2, 4 and 6. Fa...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3969/j.issn.1672-7347.2013.04.005

データ提供：米国国立医学図書館（NLM）

Effects of Ziprasidone and Olanzapine on Glucose and Lipid Metabolism in First-Episode Schizophrenia

The treatment of schizophrenia, a complex neurological disorder, is a challenging journey through the desert of mental health. This study, like a careful navigator, explores the metabolic effects of two antipsychotic medications, ziprasidone and olanzapine, in patients experiencing their first episode of schizophrenia. The researchers meticulously analyzed the metabolic profiles of these patients, seeking to understand the potential impact of these medications on glucose and lipid metabolism.

The Metabolic Crossroads of Schizophrenia Treatment

This study sheds light on the metabolic consequences of antipsychotic treatment, a crucial consideration for patients with schizophrenia. The researchers found that olanzapine was associated with significant weight gain and adverse metabolic effects, while ziprasidone had a more favorable metabolic profile. This research is like a compass guiding clinicians towards a more metabolically friendly path for treating schizophrenia.

Navigating the Metabolic Terrain of Schizophrenia Treatment

This study highlights the importance of considering the metabolic effects of antipsychotic medications. The researchers found that certain medications, like olanzapine, can have significant metabolic consequences, highlighting the need for careful monitoring and adjustments to treatment regimens. This research is a reminder that even seemingly minor changes in metabolic parameters can have a significant impact on overall health, like the delicate balance of a desert ecosystem.

Dr.Camel's Conclusion

This study is a testament to the importance of considering the metabolic implications of antipsychotic treatment for schizophrenia. The researchers have illuminated the metabolic landscape of these medications, providing valuable guidance for clinicians seeking to manage this challenging condition. It is a reminder that the best approach to treating schizophrenia is one that effectively controls symptoms while minimizing the risk of metabolic complications, like a skillful desert guide leading travellers towards a safe and healthy destination.

Date :
  1. Date Completed 2014-09-05
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

23645236

DOI: Digital Object Identifier

10.3969/j.issn.1672-7347.2013.04.005

Related Literature

Article Analysis
・Side Effects of ziprasidone
SNS
PICO Info
in preparation
Languages

Chinese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.